Document:

exv10w15

Exhibit 10.15

FIRST AMENDMENT

TO THE TENTH AMENDED AND RESTATED

SYSCO CORPORATION

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

     THIS FIRST AMENDMENT TO THE TENTH AMENDED AND RESTATED SYSCO CORPORATION SUPPLEMENTAL
EXECUTIVE RETIREMENT PLAN (this “Amendment”).

     WHEREAS, Sysco Corporation (the “Corporation”) established the Sysco Corporation
Supplemental Executive Retirement Plan (the “SERP”), originally effective July 3, 1988, to
provide certain highly compensated management personnel a supplement to their retirement pay so as
to retain their loyalty and to offer them a further incentive to maintain and increase their
standard of performance; and

     WHEREAS, the Board of Directors of the Corporation (the “Board”) has adopted that
certain Tenth Amended and Restated Sysco Corporation Supplemental Executive Retirement Plan (the
“Plan”) pursuant to a plan document effective generally as of August 27, 2010; and

     WHEREAS, pursuant to Section 10.1 of the Plan, the Compensation Committee (the
“Committee”) of the Board may amend the Plan at any time as the Committee deems advisable
by an instrument in writing; and

     WHEREAS, the Committee has determined that it is in the best interests of the Corporation and
its stockholders to amend the Plan to limit the participation of employees of the Corporation in
the Plan to those employees who are Participants in the Plan as of May 20, 2011.

     NOW, THEREFORE, the Plan is hereby amended as follows, effective as of May 20, 2011.

(Capitalized terms used but not otherwise defined herein shall have the meaning given them in the
Plan.)

     1. Section 2.1 of the Plan is hereby deleted in its entirety and replaced with the following:

     “2.1 Eligibility. Unless otherwise determined by the Compensation
Committee in its sole discretion, only those Company employees who were Participants in the Plan as
of May 20, 2011 shall be eligible to participate in the Plan. For purposes of clarification, this
Section 2.1 is not applicable to the Program, which has unique eligibility requirements as set
forth in Section 2.1 of the Program.”

 

 

     IN WITNESS WHEREOF, The Corporation has caused this First Amendment to be executed this 27th
day of May, 2011, effective as set forth herein.

	 	 	 	 	 	 	 

	 	 	SYSCO CORPORATION	 	 
	 
	 	 	 	 	 	 
	 

	 	By:

Name:
	 	/s/ Russell T. Libby
 

Russell T. Libby
	 	 
	 

	 	Title:
	 	Vice President, General Counsel
and Corporate Secretary	 	 

ATTEST:

	 	 	 	 	 

	By: 

Name:

	 	/s/ Thomas P. Kurz
 

Thomas P. Kurz
	 	 
	Title:

	 	Vice President, Deputy General Counsel	 	 
	 

	 	and Assistant Secretaryexv10w46

Exhibit 10.46

Summary of Compensation Arrangements with Named Executive Officers

(As of August 15, 2011)

The following summarizes, as of August 15, 2011, the cash compensation and benefits received by the
Company’s President and Chief Executive Officer and the other officers who will be named in the
Summary Compensation Table in the proxy statement for the Company’s upcoming Annual Meeting of
Stockholders (collectively, the “Named Executive Officers”). The following is a summary of existing
oral at-will arrangements, and does not provide any additional rights.

The executive officers of the Company serve at the discretion of the Board of Directors. The
Compensation Committee of the Board (the “Committee”) reviews and determines the compensation and
benefits that are paid to the Company’s executive officers, including the Named Executive Officers.

The current salaries of the Named Executive Officers are as follows:

	 	 	 	 	 

	William J. DeLaney
	 	$	1,150,000	 
	President and Chief Executive Officer
	 	 	 	 
	 
	 	 	 	 
	Robert C. Kreidler
	 	$	600,000	 
	Executive Vice President and Chief Financial Officer
	 	 	 	 
	 
	 	 	 	 
	Michael W. Green
	 	$	650,000	 
	Executive Vice President, Foodservice Operations
	 	 	 	 
	 
	 	 	 	 
	Larry G. Pulliam
	 	$	600,000	 
	Executive Vice President, Foodservice Operations
	 	 	 	 
	 
	 	 	 	 
	James D. Hope
	 	$	525,000	 
	Executive Vice President, Business Transformation
	 	 	 	 

The Named Executive Officers are also eligible to participate in the Company’s executive and
regular benefit plans and programs, as described below. All executive benefit plans and agreements
are filed as exhibits to the Company’s Exchange Act filings. Information regarding these plans and
agreements, as well as compensation paid or earned during fiscal 2011, will be included in the
Company’s 2011 Proxy Statement.

Management Incentive Plan

The Named Executive Officers are eligible to receive an annual incentive bonus under the Sysco
Corporation Management Incentive Plan (the “MIP”).

Deferred Compensation Election

MIP participants, including the Named Executive Officers, may defer up to 40% of their annual
incentive bonus under the Executive Deferred Compensation Plan (“EDCP”). They may also elect to
defer all or a portion of their salary under the EDCP. For deferrals of up to 20% of the

 

annual incentive bonus, the EDCP provides for Sysco to credit the participant’s deferred
compensation account in an amount equal to 15% of the amount deferred.

Stock Options, Restricted Stock and Restricted Stock Units

The Named Executive Officers are eligible to receive options under Sysco’s stock option plans,
including the 2007 Stock Incentive Plan, in such amounts and with such terms and conditions as
determined by the Committee at the time of grant. The 2007 Stock Incentive Plan also allows for the
issuance of restricted stock grants and restricted stock units.

Cash Performance Unit Plan

The Named Executive Officers are eligible to participate in the Sysco Corporation 2008 Cash
Performance Unit Plan.

Supplemental Executive Retirement Plan

The Named Executive Officers are also eligible to participate in a Supplemental Executive
Retirement Plan (the “SERP”).

Other Benefits

The Named Executive Officers also participate in Sysco’s regular employee benefit programs, which
include a defined benefit retirement plan, a 401(k) plan with Company match, group medical and
dental coverage, group life insurance and other group benefit plans. They are also provided with
additional life insurance benefits, as well as long-term disability coverage and certain
perquisites and personal benefits.exv10w1

Exhibit 10.1

AMENDED AND RESTATED LICENSE AGREEMENT

     This Amended and Restated License Agreement (the “Agreement”) is entered into as of
August 19, 2011 (the “Restatement Date”), by and between Universal Biosensors Pty Ltd, ACN
098 234 309, a company incorporated in Victoria, Australia, of 1 Corporate Avenue, Rowville,
Victoria 3178, Australia (“UBS”), and LifeScan, Inc., a California corporation
having its principal place of business at 1000 Gibraltar Drive, Milpitas, California 95035
(“LifeScan”).

     Whereas, Universal Biosensors, Inc., a Delaware corporation and UBS’s parent company
(“UBI” and, collectively with UBS, “Universal Biosensors”), and LifeScan are parties to that
certain License Agreement dated April 1, 2002, as amended on December 7, 2005, and October 25, 2007
(collectively, the “Original Agreement”), pursuant to which LifeScan granted UBI a license in and
to certain know-how, patents and patent applications relating to electrochemical sensors acquired
by LifeScan from USF Filtration and Separations Group Inc. (“FSG”);

     Whereas, UBS is the operating entity of the Universal Biosensors organization and the
holder of all intellectual property rights of the Universal Biosensors organization, and UBI’s
primary assets are the outstanding shares of UBS;

     Whereas, UBI desires that UBS be the counter-party to LifeScan under this Agreement;

     Whereas, UBI, UBS and LifeScan were also parties to that certain Development and
Research Agreement dated April 1, 2002, as amended on March 31, 2004, December 21, 2004, December
7, 2005, June 1, 2007, October 25, 2007, and May 14, 2009 (collectively, the “D&R Agreement”),
pursuant to which LifeScan granted UBI certain licenses under the “Joint Know-How” and “UNIVERSAL
BIOSENSORS’ Know-How” (as each such term was defined in the D&R Agreement);

     Whereas, LifeScan assigned the D&R Agreement to LifeScan’s Affiliate, Cilag GmbH
International (“Cilag”), on January 1, 2008;

     Whereas, concurrently herewith, UBS and Cilag have entered into an Amended and
Restated Development and Research Agreement dated as of the Restatement Date (the “Amended and
Restated D&R Agreement”);

     Whereas, in order to preserve UBS’s rights and licenses with respect to all Joint
Know-How and Universal Biosensors Know-How (as each such term is defined herein), developed before
LifeScan’s assignment of the D&R Agreement to Cilag, the parties desire to amend this Agreement to
include the grant to UBS of the licenses with respect to all Joint Know-How and Universal
Biosensors Know-How owned by LifeScan that were originally in the D&R Agreement; and

     Whereas, UBS and LifeScan now desire to amend and restate the Original Agreement in
its entirety on the terms and conditions set forth herein.

1

 

     Now, Therefore, in consideration of the premises and mutual covenants herein
contained, the parties agree to the following:

1. Definitions.

     1.1 “Affiliate” means any entity that directly or indirectly controls, is controlled by, or is
under common control with a party to the Agreement. “Control” shall mean the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of the
entity, whether through the ownership of voting securities, by contract or otherwise.

     1.2 “Assignment Date” means January 1, 2008.

     1.3 “Development” means a modification of a component, device, material, or process.

     1.4 “Effective Date” means April 1, 2002.

     1.5 “Field” means a field-of-use.

     1.6 “First Commercial Sale” means the first transfer of a Product to a third party for
monetary or other consideration; provided, however, that the transfer of a Product for use in
research and development activities (whether or not for monetary or other consideration) prior to
commercial launch of the Product shall not be considered a “First Commercial Sale.”

     1.7 “Joint Know-How” means all information, technology, and Developments developed jointly by,
or at the joint instruction of, employees or agents of both, on the one hand, LifeScan or Cilag
and, on the other hand, UBS or UBI, in the course of carrying out the Program, including, without
limitation, ideas, techniques, processes, practices, trade secrets, methods, knowledge, know-how,
skill, expertise, test data and results, analytical and quality control data, results or
descriptions, device, delivery systems, compounds, compositions of matter and material and all
improvements thereto.

     1.8 “Licensed Patents” means those United States patents identified on Exhibit C attached
hereto and made a part hereof, as well as any foreign counterparts, divisions, continuations,
continuations-in-part, renewals, reissues, re-examinations, and patents issuing therefrom,
extensions and substitutions thereof, and certificates of invention and applications for
certificates of invention with respect to the inventions claimed therein.

     1.9 “LifeScan Acquired Know-How” means all know-how, data, and information acquired from FSG
by LifeScan and related to the LifeScan Acquired Patents.

     1.10 “LifeScan Acquired Patents” means those applications and patents acquired by LifeScan
from FSG and identified on Exhibit A attached hereto and made a part hereof, as well as any patents
issuing therefrom, foreign counterparts, divisions, continuations, continuations-in-part, renewals,
reissues, re-examinations, and patents issuing therefrom, extensions and substitutions thereof, and
certificates of invention and applications for certificates of invention with respect to the
inventions claimed therein.

2

 

     1.11 “LifeScan Intellectual Property” means any and all intellectual property and the rights
therein including, without limitation, inventions, ideas, discoveries, trade secrets, know-how,
technology, software, designs, circuit layout rights, concept, data or formulae owned or controlled
by LifeScan.

     1.12 “LifeScan Other Patents” means patent applications and patents claiming Joint Know-How or
Universal Biosensors Know-How that, in each case, was developed prior to the Assignment Date,
excluding any such Joint Know-How or Universal Biosensors Know-How and patent applications and
patents therefor for which LifeScan either declined the assignment thereof from, or assigned back
to, UBI or UBS.

     1.13 “LifeScan’s Field” means diabetes, including, without limitation:

          (a) the measurement of analytes for purposes of diagnosing, managing, monitoring,
prognosticating, treating, or curing diabetes;

          (b) the collection or analysis of data for the purpose of diabetes management;

          (c) the delivery of one or more therapeutic agents for the purpose of treating or managing
abnormal glucose metabolism, including, without limitation, the delivery of insulin, insulin
analogs, Glucagon-like proteins/peptides (“GLPs”), analogs of GLPs or GLP like hormones; and

          (d) the measurement of glucose in humans for any other purpose, including, without limitation,
tight glycemic control.

     1.14 “MESA Patents” means United States Patent Nos. 6,716,577 and 7,498,132, as well as any
patents issuing therefrom, foreign counterparts, divisions, continuations, continuations-in-part,
renewals, reissues, re-examinations, and patents issuing therefrom, extensions and substitutions
thereof, and certificates of invention and applications for certificates of invention with respect
to the inventions claimed therein.

     1.15 “Patent Fees” means filing, prosecution and maintenance fees paid by LifeScan to third
parties (e.g., the USPTO and other patent offices in the Agreed Jurisdictions (defined in Section
4.1(a)), outside patent counsel, and third party patent translation service providers) with respect
to the LifeScan Acquired Patents in the Agreed Jurisdictions directed to inventions within the UBS
Fields.

     1.16 “Product” means an article within the UBS Fields that either falls within the scope of a
Valid Claim of one of the LifeScan Acquired Patents or embodies LifeScan Acquired Know-How.

     1.17 “Program” means research conducted by UBS in LifeScan’s Field jointly with, or as
directed by, LifeScan or Cilag in the course of carrying out UBI’s responsibilities under Article 2
of the D&R Agreement or UBS’s responsibilities under Article 2 of the Amended and Restated D&R
Agreement.

3

 

     1.18 “Strip Patents” means United States Patent Application Nos. 11/138,080 and 11/284,136, as
well as any patents issuing therefrom, foreign counterparts, divisions, continuations,
continuations-in-part, renewals, reissues, re-examinations, and patents issuing therefrom,
extensions and substitutions thereof, and certificates of invention and applications for
certificates of invention with respect to the inventions claimed therein.

     1.19 “Term” means the period beginning on the Effective Date and, unless terminated earlier
pursuant to Article 5, ending at the end of the term of the last to expire of the LifeScan Acquired
Patents, Licensed Patents, Strip Patents, and MESA Patents.

     1.20 “UBS Fields” means all Fields outside of LifeScan’s Field.

     1.21 “Universal Biosensors Know-How” means all information, technology, and Developments
developed solely by, or at the sole instruction of, an employee or agent of UBS or UBI, in the
course of carrying out the Program, including, without limitation, ideas, techniques, processes,
practices, trade secrets, methods, knowledge, know-how, skill, expertise, test data and results,
analytical and quality control data, results or descriptions, devices, delivery systems, compounds,
compositions of matter, and materials and all improvements thereto.

     1.22 “Valid Claim” means a claim of an issued, unexpired patent that has not been held invalid
by a court of competent jurisdiction or held unpatentable in a re-examination procedure in the
United States Patent and Trademark Office.

2. License.

     2.1 (a) Subject to the provisions of Section 2.2 and Article 3, as of the Effective Date and
for the Term, LifeScan hereby grants to UBS a worldwide, royalty-free, exclusive license, with the
right to sublicense, to make, have made, use, and sell under and exploit in any way the LifeScan
Acquired Patents and the LifeScan Acquired Know-How in the UBS Fields.

          (b) In order to exercise UBS’s rights to sublicense any or all of the rights licensed under
Section 2.1(a), UBS shall provide that each sublicense contains the terms and conditions set forth
in Article 3 and Section 4.6 of this Agreement.

     2.2 The license granted in Section 2.1(a) is subject to a reserved non-exclusive license in
LifeScan and its Affiliates to make, have made, use, and sell under and exploit in any way the
LifeScan Acquired Patents and LifeScan Acquired Know-How in the UBS Fields.

     2.3 In consideration of the license granted in Section 2.1(a), UBS hereby grants to LifeScan a
worldwide, royalty-free, irrevocable, non-exclusive license to make, have made, use, and sell under
and exploit in any way in LifeScan’s Field any and all intellectual property resulting from UBS’s
improvements, modifications, or adaptations whether or not patentable, in respect of the LifeScan
Acquired Patents, LifeScan Acquired Know-How, or both (collectively, “Improvements”).

          (a) All right, title and interest in and to the Improvements shall be in UBS, and UBS at its
sole discretion may, if registerable, register any of the Improvements in such territories (if any)
that UBS chooses.

4

 

          (b) UBS shall, at LifeScan’s expense, grant registerable user or license agreements in respect
of any registered intellectual property in any Improvements that LifeScan determines is required in
any particular territory to make the license in this Section 2.3 effective.

          (c) Registered user or license agreements under Section 2.3(b) shall be consistent with this
Section 2.3, but otherwise shall be in usual or common form.

     The license granted to LifeScan by UBS in this Section 2.3 shall include the right to
sublicense to LifeScan’s Affiliates.

     2.4 Effective as of October 25, 2007, LifeScan hereby grants to UBS a worldwide, royalty-free,
non-exclusive license, with the right to sublicense, to make, have made, use, and sell under and
exploit in any way the Licensed Patents in the UBS Fields. The license granted in this Section 2.4
shall last until expiration of the last to expire of the Licensed Patents. This Section 2.4 shall
survive the expiration or termination of this Agreement.

     2.5 LifeScan hereby grants to UBS a paid-up, non-exclusive license to use the LifeScan
Intellectual Property in LifeScan’s Field only to the extent and for the period of time necessary
that such LifeScan Intellectual Property is required by UBS to provide one or both of development
and supply services to LifeScan or a LifeScan Affiliate.

     2.6 LifeScan hereby grants to UBS a perpetual, royalty-free, paid-up, exclusive, worldwide
right and license, with the right to sublicense, to make, have made, use and sell under and
otherwise exploit in any way the Joint Know-How and Universal Biosensors Know-How developed prior
to the Assignment Date, and the LifeScan Other Patents, in each case in the UBS Fields.

     2.7 Effective as of the Restatement Date, LifeScan hereby grants to UBS a perpetual,
royalty-free, paid-up, exclusive, worldwide right and license, with the right to sublicense, to
make, have made, use and sell under and otherwise exploit in any way the MESA Patents in the UBS
Fields.

     2.8 Effective as of the Restatement Date, UBS hereby grants to LifeScan a perpetual,
royalty-free, paid-up, exclusive, worldwide right and license, with the right to sublicense, to
make, have made, use and sell under and otherwise exploit in any way the Strip Patents in
LifeScan’s Field.

     2.9 Promptly after the Restatement Date, and to the extent not previously transferred to
LifeScan, UBS shall transfer to LifeScan all Joint Know-How or Universal Biosensors Know-How, in
each case developed prior to the Assignment Date, existing as at that date. Such information shall
include, without limitation, copies of all relevant data, drawings, notebooks, and samples.

3. Recapture Rights

     3.1 In order for UBS to maintain the exclusive license granted in Section 2.1(a), UBS shall
use commercially reasonable efforts to use and exploit the LifeScan Acquired Patents and LifeScan
Acquired Know-How in the UBS Fields directly or through any of UBS’s Affiliates or

5

 

sublicensees; provided, however, that UBS retains the discretion to determine the means and
manner of its exploitation of LifeScan Acquired Patents and LifeScan Acquired Know-How. For
purposes of this Article 3:

          (a) “commercially reasonable efforts” means, with respect to UBS’s obligation under this
Agreement to use and exploit the LifeScan Acquired Patents and LifeScan Acquired Know-How in the
UBS Fields, the level of efforts required to carry out such obligation in a sustained manner
consistent with the efforts similarly-situated medical diagnostics companies devote to a product of
similar market potential, profit potential or strategic value resulting from their own research
efforts, based on conditions then prevailing;

          (b) “similarly-situated medical diagnostics company” means a company in the medical
diagnostics industry of a size and stage of development (taking into account, without limitation,
market capitalizations, revenues, number of employees, resources, and manufacturing capabilities)
similar to that of UBS; and

          (c) “exploit” or “exploitation” means:

               (i) using in research and development activities;

               (ii) using in developing, making, selling, and distributing Products;

               (iii) granting sublicenses in any Field within the UBS Fields; and

               (iv) developing, in conjunction with Section 3.1(c)(i), 3.1(c)(ii) or 3.1(c)(iii), new patent
applications or other intellectual property that derives from or, is a development of, any of the
LifeScan Acquired Patents and LifeScan Acquired Know-How in the UBS Fields.

     3.2 During the Term, UBS shall provide to LifeScan periodic, written, summary reports on UBS’s
exploitation plans and any Improvements to which Section 2.3 applies, which reports shall be
provided at least one (1) time per calendar year. LifeScan shall keep confidential any
exploitation plans disclosed to it under this Section 3.2.

     3.3 In the event that LifeScan is approached by a third party that desires a license in a
Field within the UBS Fields in any or all of the LifeScan Acquired Patents or LifeScan Acquired
Know-How, LifeScan shall refer the third party to UBS by identifying the third party, identifying a
contact for the third party, and providing UBS copies of any correspondence received by LifeScan
from the third party (collectively, a “Referral”). UBS shall acknowledge in writing to LifeScan
receipt of the Referral within 30 days of such receipt.

     3.4 If UBS receives a Referral pursuant to Section 3.3, UBS shall enter into good faith
negotiations for the grant of a license to the third party unless UBS (directly or through any of
its Affiliates or sublicensees):

          (a) is engaged in exploitation of the LifeScan Acquired Patents or LifeScan Acquired Know-How,
as applicable, in the Field that is the subject of the Referral; or

6

 

          (b) provides to LifeScan evidence that reasonably demonstrates to LifeScan that UBS has bona
fide plans to commence exploitation of the LifeScan Acquired Patent or LifeScan Acquired Know-How,
as applicable, in the Field within 12 months of the date of UBS’s acknowledgment of the Referral.

     3.5 If UBS fails to enter into negotiations under Section 3.4 within three (3) months of the
date of UBS’s acknowledgment of the Referral, LifeScan shall have the right to convert the license
granted under Section 2.1(a) to a non-exclusive license with respect to the Field and LifeScan
Acquired Patent or LifeScan Acquired Know-How that is the subject of the Referral.

4. Patent Prosecution and Maintenance; Patent Marking.

     PART A: LifeScan Acquired Patents, Licensed Patents and MESA Patents.

     4.1 (a) LifeScan shall accept liaison and financial responsibility for prosecution by a patent
attorney, in independent practice nominated by LifeScan and approved by UBS, of the application or
applications within the LifeScan Acquired Patents that, in each case, are directed to inventions
within the UBS Fields to allowance or to the point of necessary appeal from a final rejection by an
Examiner of the USPTO, and those jurisdictions listed on Exhibit B attached hereto and made a part
hereof and any other jurisdiction mutually agreed upon by the parties (the jurisdictions listed on
Exhibit B and such other mutually agreed jurisdictions, collectively, the “Agreed Jurisdictions”).

          (b) Except as may be later separately agreed upon by the parties in writing, LifeScan does not
accept responsibility for:

               (i) filing or prosecution of any appeal from a final rejection by an Examiner of the USPTO, or
any other jurisdiction, of any of the patent applications; or

               (ii) the conduct of any interference in which an application or patent arising from an
application may become involved.

     4.2 LifeScan will furnish UBS copies of all office actions and LifeScan’s proposed responses
thereto at least 30 days prior to the earliest date set by the USPTO or corresponding foreign
office for submission of the response and UBS shall have the right to review and comment on
LifeScan’s proposed response to such action.

     4.3 In the event that LifeScan elects not to proceed with the prosecution of an application
under Section 4.1(a), LifeScan shall notify UBS of such decision and UBS shall have the right at
any time thereafter to assume and continue at its own expense the prosecution of the application.
Upon receipt by UBS of such notice from LifeScan, LifeScan:

          (a) shall be relieved of all further financial and other responsibility in respect to the
application;

          (b) shall have no further rights thereto in all jurisdictions for which UBS assumes financial
responsibility for the prosecution;

7

 

          (c) shall enter into such assignments or other reasonably necessary documents in respect
thereto in all jurisdictions for which UBS assumes financial responsibility so as to properly vest
ownership and the right to prosecute the application in UBS or its nominee; and

          (d) shall provide to UBS the file histories of the application in LifeScan’s possession.

     4.4 Upon issuance of any patents resulting from the applications prosecuted pursuant to
Section 4.1(a), LifeScan will accept responsibility for payment of maintenance fees for all
jurisdictions mutually agreed upon by the parties. However, LifeScan shall have the right to
discontinue the payment of any or all maintenance fees in any or all countries. In the event
LifeScan discontinues such maintenance payments, LifeScan shall notify UBS of such decision and UBS
may, at its option, maintain the patent solely at its own expense. Upon receipt by UBS of such
notice from LifeScan, LifeScan:

          (a) shall be relieved of all further financial and other responsibility in respect to the
patent at issue;

          (b) shall have no further rights thereto in all jurisdictions for which UBS has assumed the
maintenance payments;

          (c) shall enter into such assignments or other reasonably necessary documents in respect
thereto in all jurisdictions for which UBS assumes financial responsibility so as to properly vest
ownership and the right to maintain the patent in UBS or its nominee; and

          (d) shall provide to UBS the file histories of the patent in LifeScan’s possession.

     4.5 (a) In the event that UBS grants a sublicense in the LifeScan Acquired Patents to a third
party (other than in conjunction with the grant to such third party of a sublicense to exploit
within the UBS Fields a Product developed by or on behalf of UBS or its Affiliate, either alone or
in collaboration with such third party) and receives any lump sum payments (including but not
limited to up-front fees and milestone payments) or actual or minimum royalty payments from the
sublicensee with respect to such sublicense (each, a “Pass-Through Sublicense Payment”), UBS agrees
to pay 50% of such Pass-Through Sublicense Payment (when received from time to time) to LifeScan in
reimbursement of the Patent Fees paid by LifeScan.

          (b) In the event that there is a First Commercial Sale of a Product by or on behalf of a third
party alone or in conjunction, partnership, collaboration or the like with UBS or its Affiliate,
which Product is developed by or on behalf of UBS or its Affiliate alone or in collaboration with
the third party, UBS agrees to pay fifty percent (50%) of the Patent Fees paid by LifeScan prior to
the date of the First Commercial Sale (the “Initial Payment”) and fifty percent (50%) of the Patent
Fees incurred by LifeScan thereafter (the “Ongoing Payment”).

               (i) UBS shall notify LifeScan of the First Commercial Sale date within 30 days thereof, and
LifeScan shall provide to UBS reasonable supporting documentation of the Patent Fees paid by
LifeScan up to the date of the First Commercial Sale.

8

 

               (ii) UBS shall have the right to elect to make the Initial Payment either as a lump sum within
45 days of the date of receipt of the supporting documentation from LifeScan or in equal monthly
installment payments during the 24 calendar months subsequent to the date of receipt of the
supporting documentation.

               (iii) LifeScan shall invoice UBS on an annual basis for the Ongoing Payment and provide
reasonable supporting documentation therefor, and payment of each such invoice shall be made within
45 days of receipt by UBS from LifeScan of the invoice and supporting documentation.

          (c) UBS shall not structure any third party transaction contemplated by Section 4.5(a) or (b)
in a manner such that the purpose of such structure is to circumvent or minimize its obligation to
make payments that would otherwise be owed to LifeScan under this Agreement.

          (d) In no event shall UBS be obligated to pay, nor shall LifeScan be entitled to receive from
UBS, cumulative amounts under Sections 4.5(a) and 4.5(b) in excess of 50% of the cumulative Patent
Fees paid by LifeScan.

               (i) UBS’s payment obligations to LifeScan under Section 4.5(a) shall cease at the end of the
term of the LifeScan Acquired Patents that are the subject of the Pass-Through Sublicense Payment
from the sublicensee.

               (ii) UBS’s payment obligations to LifeScan under Section 4.5(b) shall cease at the end of the
term of the LifeScan Acquired Patents within the claims of which the Product falls.

          (e) LifeScan acknowledges to UBS that, apart from the rights to payments under Sections 4.5(a)
and 4.5(b), LifeScan is not entitled to receive any other amount by way of royalty or similar
payment in respect of the license granted herein.

     4.6 UBS agrees to place in a conspicuous location on products sold to third parties a patent
notice, in accordance with 35 U.S.C. §287, and any corresponding provision of the laws of a
jurisdiction other than the United States in which a Product is being sold, identifying the
relevant LifeScan Acquired Patents, Licensed Patents, LifeScan Other Patents, or MESA Patents, if
any.

PART B: LifeScan Other Patents

     4.7 (a) LifeScan will, at LifeScan’s sole discretion, accept liaison and financial
responsibility for:

               (i) preparation, by a patent attorney in independent practice nominated by LifeScan and
approved by UBS, of LifeScan Other Patents;

               (ii) filing upon execution by the inventors of such application or applications within the
LifeScan Other Patents at least in the Agreed Jurisdictions, provided that

9

 

UBS may elect, at its own expense, to file the application or applications in additional
countries; and

               (iii) prosecution by the attorney of such application or applications to allowance or to the
point of necessary appeal from a final rejection by an examiner in the Agreed Jurisdictions.

          (b) Except as may be later separately agreed upon by the parties in writing, LifeScan does not
accept responsibility for:

               (i) filing or prosecution of any appeal from a final rejection by and examiner in any of the
Agreed Jurisdictions of any patent application within the LifeScan Other Patents; or

               (ii) the conduct of any interference in which an application or applications within the
LifeScan Other Patents may become involved.

          (c) LifeScan will furnish UBS copies of:

               (i) any applications filed pursuant to Section 4.7(a)(i);

               (ii) any substantive office actions received from any of the Jurisdictions, pertaining to the
applications filed pursuant to Section 4.7(a)(ii); and

               (iii) any substantive responses to office actions filed pursuant to Section 4.7(a)(iii).

          (d) UBS shall assist, as is deemed necessary by LifeScan, in preparing, filing, and
prosecuting the applications filed pursuant to this Section 4.7 and maintaining and defending the
patents issuing therefrom. During the Term, such assistance shall be at no cost to LifeScan or its
Affiliates except for the costs of travel and accommodations for travel requested by LifeScan or
its Affiliates. After expiration or termination of the Agreement, such assistance shall be at
LifeScan’s cost.

          (e) In the event that LifeScan elects not to proceed with the filing or prosecution of any
application under this Section 4.7, respectively, UBS shall have the right at any time thereafter
and by written notice to LifeScan to assume and continue at its own expense filing, prosecution, or
both of the application. Upon receipt by LifeScan of such notice, LifeScan:

               (i) shall be relieved of all further financial and other responsibility in respect to the
application;

               (ii) shall have no further rights thereto in all countries for which UBS has assumed the
payments;

               (iii) shall enter into such assignments or other reasonably necessary documents in respect
thereto in all countries for which UBS assumes financial responsibility so

10

 

as to properly vest ownership and the right to prosecute the application in UBS or its
nominee; and

               (iv) shall provide to UBS the file histories of the application in LifeScan’s possession.

          (f) Upon issuance of any patents resulting from applications filed pursuant to Section
4.7(a)(ii), LifeScan will accept responsibility for payment of maintenance fees for the Agreed
Jurisdictions and all other countries elected by LifeScan. However, LifeScan shall have the right
at any time to discontinue the payment of any or all maintenance fees in any or all such countries.
In the event LifeScan discontinues such maintenance payments, UBS may, at its option and by
written notice to LifeScan, maintain the patent at its own expense and license it to third parties.
Upon receipt by LifeScan of such notice, LifeScan:

               (i) shall be relieved of all further financial and other responsibility in respect to the
patent at issue;

               (ii) shall have no further rights thereto in all countries for which UBS has assumed the
payments;

               (iii) shall enter into such assignments or other reasonably necessary documents in respect
thereto in all countries for which UBS assumes financial responsibility so as to properly vest
ownership and the right to maintain the patent in UBS or its nominee; and

               (iv) shall provide to UBS the file histories of the patent in LifeScan’s possession.

5. Termination.

     5.1 This Agreement shall extend until the end of the Term unless terminated earlier in
accordance with this Article 5.

     5.2 This Agreement may be terminated by LifeScan in the event that UBS fails to use
commercially reasonable efforts to exploit the LifeScan Acquired Patents and LifeScan Acquired
Know-How. For purposes of this Section 5.2:

          (a) “commercially reasonable efforts” and “exploit” have the same meaning as in Section 3.1;
and

          (b) if LifeScan wishes to terminate the Agreement pursuant to this Section 5.2, LifeScan shall
first provide UBS with 90 days’ written notice of its intent to so terminate and, if at the
expiration of the 90 days, UBS has not provided evidence to LifeScan that UBS is using commercially
reasonable efforts to exploit the LifeScan Acquired Patents and the LifeScan Acquired Know-How,
this Agreement shall terminate on the 91st day.

     5.3 This Agreement may be terminated by LifeScan in the event that UBS is liquidated or is
wound up or is in persistent and material breach of its obligations under this Agreement. LifeScan
shall first provide UBS with 90 days’ written notice of its intent to so

11

 

terminate and, if at the expiration of the 90 days, UBS has not rectified the breach, this
Agreement shall terminate on the 91st day.

     5.4 In the event that LifeScan terminates this Agreement pursuant to Section 5.2 or Section
5.3, any sublicense previously granted by UBS to a third party under the Acquired LifeScan Patents,
Acquired LifeScan Know-How or both that is in effect immediately prior to such termination shall
survive such termination as a direct license from LifeScan to such sublicensee on the terms and
conditions set forth in this Agreement, provided that the sublicensee: (a) is not in material
breach of any provision of this Agreement; and (b) agrees to be bound to LifeScan as a licensor
under the terms and conditions of this Agreement, except that the sublicensee’s obligation under
Section 3.1 shall be limited to the Field(s) within the UBS Fields in which UBS granted such
sublicensee a sublicense under the Acquired LifeScan Patents, Acquired LifeScan Know-How or both.

     5.5 The provisions of this Agreement that by their terms are meant to survive termination or
expiration, including Sections 2.4, 2.5 (solely to the extent that UBS has any continuing
obligation under a separate agreement to provide one or both of development and supply services to
LifeScan or a LifeScan Affiliate), 2.6, 2.7, 2.8, 5.4 and 5.5 and Articles 7, 8, 9 and 10, shall
survive termination or expiration of the Agreement.

6. Enforcement of Patents.

PART A: LifeScan Acquired Patents and MESA Patents.

     6.1 (a) In the event that UBS becomes aware of any actual or alleged unlicensed infringement
of a LifeScan Acquired Patent or MESA Patent within one of the UBS Fields, UBS shall bring such
infringement to LifeScan’s attention in writing (such writing, a “LifeScan Patent Infringement
Notice”), and LifeScan shall have the first right, but not the obligation, to:

               (i) secure cessation of the infringement;

               (ii) enter suit against the infringer; or

               (iii) engage, along with UBS, in bona fide negotiations for the acceptance by the infringer of
a sublicense under the patents on terms mutually agreeable to LifeScan and UBS.

Any recovery realized by LifeScan as a result of any litigation, other enforcement activity or
execution of a sublicense within any UBS Fields as described in this Section 6.1(a) (whether by way
of damages, profits, awards, settlement or otherwise) shall be first allocated to reimbursement of
unreimbursed external legal fees and expenses incurred by LifeScan, and then toward reimbursement
of any of unreimbursed external legal fees and expenses of UBS, and then the remainder shall be
shared by the parties, with LifeScan retaining fifty percent (50%) of such remainder and paying to
UBS fifty percent (50%) of such remainder.

          (b) If, within six (6) months of receipt of a LifeScan Patent Infringement Notice, LifeScan
has not secured cessation of the infringement or entered suit against the infringer, and LifeScan,
UBS and the infringer have not entered into a sublicense, then UBS shall

12

 

thereafter have the right to sue for the infringement at its own expense, and any recovery
realized by UBS as a result thereof (whether by way of damages, profits, awards, settlement or
otherwise) shall first be allocated to reimbursement of unreimbursed external legal fees and
expenses incurred by UBS, and then toward reimbursement of any of unreimbursed external legal fees
and expenses of LifeScan, and then the remainder shall be shared by the parties, with UBS retaining
fifty percent (50%) of such remainder and paying to LifeScan fifty percent (50%) of such remainder.

          (c) In the event a party brings an infringement action in accordance with this Section 6.1:

               (i) the other parties shall cooperate fully, including, if required to bring such action, the
furnishing of a power of attorney or being named as a party;

               (ii) neither party shall have the right to settle any patent infringement litigation under
this Section 6.1 with respect to infringement of a LifeScan Acquired Patent or MESA Patent within
the UBS Fields without the prior written consent of the other party, which shall not be
unreasonably withheld or delayed; and

               (iii) the party bringing the infringement action shall incur no liability to the other party
as a consequence of such litigation or any unfavorable decision resulting therefrom including any
decision holding the patent invalid or unenforceable.

     6.2 Nothing in this Agreement shall be construed as an obligation on LifeScan’s part to
enforce or defend the LifeScan Acquired Patents, or MESA Patents.

PART B: Strip Patents.

     6.3 (a) In the event that LifeScan becomes aware of any actual or alleged unlicensed
infringement of a Strip Patent within LifeScan’s Field, LifeScan shall bring such infringement to
UBS’s attention in writing (such writing, a “Strip Patent Infringement Notice”) and UBS shall have
the first right, but not the obligation to:

               (i) secure cessation of the infringement;

               (ii) enter suit against the infringer; or

               (iii) engage, along with LifeScan, in bona fide negotiations for the acceptance by the
infringer of a sublicense under the patents on terms mutually agreeable to LifeScan and UBS.

Any recovery realized by UBS as a result of any litigation, other enforcement activity or execution
of a sublicense within LifeScan’s Field as described in this Section 6.3(a) (whether by way of
damages, profits, awards, settlement or otherwise) shall be first allocated to reimbursement of
unreimbursed external legal fees and expenses incurred by UBS, and then toward reimbursement of any
of unreimbursed external legal fees and expenses of LifeScan, and then the remainder shall be
shared by the parties, with UBS retaining fifty percent (50%) of such remainder and paying to
LifeScan fifty percent (50%) of such remainder.

13

 

          (b) If, within six (6) months of receipt of a Strip Patent Infringement Notice, UBS has
not secured cessation of the infringement or entered suit against the infringer, and LifeScan, UBS
and the infringer have not entered into a sublicense, then LifeScan shall thereafter have the right
to sue for the infringement at its own expense, and any recovery realized by LifeScan as a result
thereof (whether by way of damages, profits, awards, settlement or otherwise) shall first be
allocated to reimbursement of unreimbursed external legal fees and expenses incurred by LifeScan,
and then toward reimbursement of any of unreimbursed external legal fees and expenses of UBS, and
then the remainder shall be shared by the parties, with LifeScan retaining fifty percent (50%) of
such remainder and paying to UBS fifty percent (50%) of such remainder.

          (c) In the event a party brings an infringement action in accordance with this Section 6.3:

               (i) the other parties shall cooperate fully, including, if required to bring such action, the
furnishing of a power of attorney or being named as a party;

               (ii) neither party shall have the right to settle any patent infringement litigation under
this Section 6.3 with respect to infringement of a Strip Patent within LifeScan’s Field without the
prior written consent of the other party, which shall not be unreasonably withheld or delayed; and

               (iii) the party bringing the infringement action shall incur no liability to the other party
as a consequence of such litigation or any unfavorable decision resulting therefrom including any
decision holding the patent invalid or unenforceable.

     6.4 Nothing in this Agreement shall be construed as an obligation on UBS’s part to enforce or
defend the Strip Patents.

PART C: LifeScan Other Patents

     6.5 UBS and LifeScan shall each give prompt notice to one another of any infringement by third
parties of the Joint Know-How or Universal Biosensors Know-How, in each case developed prior to the
Assignment Date, or LifeScan Other Patents licensed hereunder as may come to its respective
knowledge. UBS shall have the right, but not the obligation, to pursue legal action against
infringement of such Joint Know-How, Universal Biosensors Know-How or LifeScan Other Patents, in
the UBS Fields by third parties, including defending any declaratory judgment action. LifeScan
shall cooperate with UBS and provide such non-monetary assistance as UBS may reasonably request in
connection with such action. LifeScan shall have the right to participate in and be represented by
independent counsel in such action at its own expense. Any recovery realized by UBS as a result of
any litigation, other enforcement activity or execution of a sublicense (whether by way of damages,
profits, awards, settlement or otherwise) shall be first allocated to reimbursement of unreimbursed
external legal fees and expenses incurred by UBS and then toward reimbursement of unreimbursed
external legal fees and expenses of LifeScan. UBS shall incur no liability to LifeScan as a
consequence of such litigation or any resulting unfavorable decision including any decision holding
any LifeScan Other Patent invalid or unenforceable.

14

 

7. Warranties

     7.1 UBS represents and warrants that: (a) it is the sole owner of all intellectual property
rights of UBS and its Affiliates; (b) that it is the sole owner of the Strip Patents; and (c) it
has assigned all right, title and interest in and to the LifeScan Other Patents to LifeScan.
LifeScan represents and warrants that it is the sole owner of the LifeScan Acquired Patents,
Licensed Patents, MESA Patents and LifeScan Other Patents. In addition, each party warrants that
it has the ability to enter into this Agreement, that to the best of their knowledge there are no
outstanding written or oral agreements to which such party is a party that are inconsistent with
the Agreement, and that it will not, while the Agreement is in force, enter into any written or
oral agreement in conflict with the Agreement.

     7.2 Nothing in this Agreement shall be construed as: (a) a warranty or representation by
LifeScan of the validity, enforceability, or scope of the LifeScan Acquired Patents, Licensed
Patents, MESA Patents or LifeScan Other Patents; or (b) a warranty or representation by UBS of the
validity, enforceability, or scope of the Strip Patents.

     7.3 Nothing in this Agreement shall be construed as: (a) a warranty or representation by
LifeScan that a Product, or a product that falls within the scope of a claim of one of the LifeScan
Acquired Patents, MESA Patents, Licensed Patents or LifeScan Other Patents, that, in each case, is
made, used, or sold by UBS, its Affiliates or its sublicensees under the licenses granted to UBS
herein is or will be free from infringement of the intellectual property of third parties; or (b) a
warranty or representation by UBS that a product that falls within the scope of a claim of one of
the Strip Patents and is made, used, or sold by LifeScan, its Affiliates or sublicensees under the
license granted to LifeScan herein is or will be free from infringement of the intellectual
property of third parties. LifeScan shall not be responsible for any award of damages arising out
of charges that UBS, alone or in combination with other entities or persons, infringed or infringes
any claim of any third party patent by making, having made, using, selling or otherwise
distributing Products, or other products that falls within the scope of a claim of one of the
LifeScan Acquired Patents, MESA Patents, Licensed Patents or LifeScan Other Patents. UBS shall not
be responsible for any award of damages arising out of charges that LifeScan, alone or in
combination with other entities or persons, infringed or infringes any claim of any third party
patent by making, having made, using, selling or otherwise distributing a product that falls within
the scope of a claim of one of the Strip Patents.

     Except as expressly set forth in Section 7.1, LIFESCAN MAKES NO WARRANTIES OF ANY NATURE WITH
RESPECT TO THE LIFESCAN ACQUIRED PATENTS, LICENSED PATENTS, MESA PATENTS, LIFESCAN OTHER PATENTS
AND LIFESCAN ACQUIRED KNOW-HOW, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY,
FITNESS FOR PARTICULAR PURPOSE, OR OTHERWISE. Except as expressly set forth in Section 7.1, UBS
MAKES NO WARRANTIES OF ANY NATURE WITH RESPECT TO THE STRIP PATENTS, INCLUDING, WITHOUT LIMITATION,
ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR OTHERWISE.

15

 

8. Notices

     All notices, reports, requests, or statements provided for in this Agreement shall be given in
writing and may be served either by personal delivery or by depositing the same, postage prepaid,
in the United States first class, certified, or registered mails (date of deposit will be
considered date of delivery) addressed to the parties respectively at the following addresses:

(a) In the case of UBS:

Chief Executive Officer

Universal Biosensors Pty Ltd

1 Corporate Avenue

Rowville, Victoria 3178

Australia

Fax: +613 9213 9099

With a copy to:

Chief Financial Officer

Universal Biosensors Pty Ltd

1 Corporate Avenue

Rowville, Victoria 3178

Australia

Fax: +613 9213 9099

And a copy to:

Beth Hughes

Venable Attorneys at Law

8010 Towers Crescent Drive

Suite 300

Vienna, Virginia 22182

USA

Fax: +1 (703) 821-8949

(b) In the case of LifeScan:

LifeScan, Inc.

1000 Gibraltar Drive

Milpitas, California 95035

Attn: President

Fax: +1 (408) 956-4701

16

 

With a copy to:

Chief Patent Counsel

Johnson & Johnson

One Johnson & Johnson Plaza

New Brunswick, New Jersey 08933 U.S.A.

Fax: +1 732-524-5008

9. Arbitration

     Any controversy or claim arising out of or relating to this Agreement or the validity,
inducement, or breach thereof, shall be settled by arbitration before a single arbitrator in
accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”)
then pertaining (available at www.adr.org), except where those rules conflict with this provision,
in which case this provision controls. Any court with jurisdiction shall enforce this clause and
enter judgment on any award. The arbitrator shall be an attorney who has at least 15 years of
experience with a law firm or corporate law department of over 25 lawyers or who was a judge of a
court of general jurisdiction. The arbitrator shall be selected within ten days of commencement of
the arbitration from the AAA’s National Roster of Arbitrators pursuant to agreement or through
selection procedures administered by the AAA. The arbitration shall be held in San Francisco,
California and in rendering the award the arbitrator must apply the substantive law of New York
(except where that law conflicts with this clause), except that the interpretation and enforcement
of this arbitration provision shall be governed by the Federal Arbitration Act. Within 45 days of
initiation of arbitration, the parties shall reach agreement upon and thereafter follow procedures
assuring that the arbitration will be concluded and the award rendered within no more than eight
months from selection of the arbitrator. Failing such agreement, the AAA will design and the
parties will follow procedures that meet such a time schedule. Each party has the right before or,
if the arbitrator cannot hear the matter within an acceptable period, during the arbitration to
seek and obtain from the appropriate court provisional remedies such as attachment, preliminary
injunction, replevin, etc., to avoid irreparable harm, maintain the status quo or preserve the
subject matter of the arbitration. THE ARBITRATOR SHALL NOT AWARD ANY PARTY PUNITIVE, EXEMPLARY,
MULTIPLIED OR CONSEQUENTIAL DAMAGES, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO SEEK
SUCH DAMAGES. NO PARTY MAY SEEK OR OBTAIN PREJUDGMENT INTEREST OR ATTORNEYS’ FEES OR COSTS.

10. General Provisions.

     10.1 This Agreement, or any of its rights and obligations, shall not be assigned or
transferred in whole or in part by either party without the prior written consent of the other
party.

          (a) Any attempted assignment or transfer of such rights or obligations without consent shall
be void.

          (b) A party shall not unreasonably withhold its consent to an assignment or transfer as part
of the sale of the whole or part of the business of the assignor or transferor if the assignee or
transferee is of reasonable financial standing.

17

 

     10.2 This Agreement shall be binding upon and inure to the benefit of the parties and their
respective successors and assigns.

     10.3 The waiver of either party, whether express or implied, of any provision of this
Agreement, or of any breach or default of either party, shall not be construed to be a continuing
waiver of such provision, or any succeeding breach or default or of a waiver of any other provision
of this Agreement.

     10.4 The interpretation, validity, and performance of this Agreement shall be governed by the
laws of the State of New York, except for such laws directing application of the laws of another
jurisdiction.

     10.5 Each party shall comply with all applicable United States and foreign governmental laws
and regulations including, without limitation, any such laws directed to importation and
exportation.

     10.6 It is the mutual desire and intent of LifeScan and UBS to provide certainty as to their
future rights and remedies against each other by defining the extent of their mutual undertaking as
provided herein. Both LifeScan and UBS acknowledge and agree: (a) that no representation or
promise not expressly contained in this Agreement has been made by the other party hereto or by any
of its agents, employees, representatives or attorneys; (b) that such Agreement is not being
entered into on the basis of, or in reliance on, any promise or representation, expressed or
implied, covering the subject matter hereof, other than those which are set forth expressly in this
Agreement; and (c) that each party has had the opportunity to be represented by counsel of its own
choice in this matter, including the negotiations which preceded the execution of this Agreement.

     10.7 This Agreement represents the entire understanding between UBS and LifeScan with respect
to the subject matter in this Agreement, and supersedes any and all implied or express
understandings, agreements or obligations between the parties with respect thereto whether written
or oral, including, without limitation, the Original Agreement.

[Signature page follows]

18

 

     In Witness Whereof, the parties hereto have duly executed this Agreement as of the
Restatement Date.

	 	 	 	 	 	 	 

	Universal Biosensors Pty Ltd	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	/s/ Paul Wright 

	 	By:
	/s/ Salesh Balak 

	 

	Name: 	Paul
Wright 

	 	
	Name: 	Salesh Balak 

	

	Title: 	CEO 

	 	 
	Title: 	CFO 

	Date: 
	8/29/11 

	 	Date: 
	8/29/11 

	 
	 	 	 	 	 	 
	LifeScan, Inc.

	 	 	 
	 
	 	 	 	 	 	 
	By:

	/s/ John Carlson 

	 	 	 	 
	

	Name: 	John
Carlson 

	 	 	 	 
	

	Title: 	Worldwide VP
R&D. 

	 	 	 	 
	Date: 

	8/25/11 

	 	 	 	 

Universal Biosensors, Inc. hereby acknowledges and agrees that this Agreement supersedes the
Original Agreement in its entirety.

	 	 	 	 	 	 	 

	Universal Biosensors, Inc.

	 	 	 
	 
	 	 	 	 	 	 
	By:

	/s/ Paul Wright 

	 	 	 	 
	

	Name: 	Paul
Wright 

	 	 	 	 
	 

	Title: 	CEO 

	 	 	 	 
	Date: 

	8/29/11 

	 	 	 	 

19

 

EXHIBIT A

LifeScan Acquired Patents

	 	 	 	 	 	 	 
	Current Docket No.	 	Title	 	Pat./Appln. No.	 	Filing/issue Date
	*LFS0196USA

	 	Electrochemical Cells
	 	US 5,863,400
	 	01/26/1999
	 
	 	 	 	 	 	 
	*LFS0197USA

	 	Method of Defining an
Electrode Area
	 	US 5,980,709
	 	11/09/1999
	 
	 	 	 	 	 	 
	LFS0198US

	 	Electrochemical Cell
	 	US 6,284,125
	 	09/04/2001
	 
	 	 	 	 	 	 
	LFS0198CNT3

	 	Electrochemical Cell
	 	US 7,608,175
	 	10/27/2009
	 
	 	 	 	 	 	 
	LFS0198USCNT4

	 	Electrochemical Cell
	 	US 7,604,722
	 	10/20/2009
	 
	 	 	 	 	 	 
	LFS0198USCNT5

	 	Electrochemical Cell
	 	USSN 12/560,773
	 	09/16/2009
	 
	 	 	 	 	 	 
	LFS0198USCNT6

	 	Electrochemical Cell
	 	USSN 12/560,780
	 	09/16/2009
	 
	 	 	 	 	 	 
	LFS0198USCNT7

	 	Electrochemical Cell
	 	USSN 12/567,433
	 	09/25/2009
	 
	 	 	 	 	 	 
	LFS0199USA

	 	Electrochemical Cell
	 	US 6,179,979
	 	01/30/2009
	 
	 	 	 	 	 	 
	LFS0199USCNT1

	 	Electrochemical Cell
	 	US 7,431,814
	 	10/07/2008
	 
	 	 	 	 	 	 
	LFS0199USCNT2

	 	Electrochemical Cell
	 	USSN 11/487,728
	 	07/17/2006
	 
	 	 	 	 	 	 
	LFS0199USRE1

	 	Electrochemical Cell
	 	USSN 12/899,342
	 	10/06/2010
	 
	 	 	 	 	 	 
	LFS0200USA

	 	Electrochemical Method
	 	US 5,942,102
	 	08/24/1999
	 
	 	 	 	 	 	 
	*LFS0201US

	 	Analytic Cell
	 	US 6,193,865
	 	02/27/2001
	 
	 	 	 	 	 	 
	*LFS0202USA

	 	Electrochemical Cell
	 	US 6,454,921
	 	09/24/2002
	 
	 	 	 	 	 	 
	LFS0203USA

	 	Sensor Connector Means
	 	US 6,379,513
	 	04/30/2002
	 
	 	 	 	 	 	 
	LFS0203USCNT2

	 	Sensor Connector Means
	 	USSN 11/434,442
	 	05/15/2006
	 
	 	 	 	 	 	 
	*LFS0204US

	 	Method and Apparatus for
Automatic Analysis
	 	US 6,325,917
	 	12/04/2001
	 
	 	 	 	 	 	 
	*LFS0205US

	 	Heated Electrochemical Cell
	 	US 6,475,360
	 	11/05/2002
	 
	 	 	 	 	 	 
	*LFS0206USA

	 	Sensor With Improved Shelf Life
	 	US 6,652,734
	 	11/25/2003
	 
	 	 	 	 	 	 
	*LFS0206USACON

	 	Sensor With Improved Shelf Life
	 	US 7,335,292
	 	02/26/2008
	 
	 	 	 	 	 	 
	*LFS0206USCON2

	 	Sensor With Improved Shelf Life
	 	USSN 11/926,369
	 	10/29/2007

 

			
	*	 	Asterisk indicates cases no longer prosecuted or maintained by J&J, for which UBS declined to
assume responsibility, and that will become abandoned in due course.

A-1

 

EXHIBIT A

	 	 	 	 	 	 	 
	Current Docket No.	 	Title	 	Pat./Appln. No.	 	Filing/issue Date
	LFS0207US

	 	Electrochemical Cell
	 	US 6,174,420
	 	01/16/2001
	 
	 	 	 	 	 	 
	*LFS0208USNP

	 	Method of
Preventing Short
Sampling of a Capillary
or Wicking Fill Device
	 	US 6,571,651
	 	06/02/2003
	 
	 	 	 	 	 	 
	*LFS0208USDIV1

	 	Method of
Preventing Short
Sampling of a Capillary
or Wicking Fill Device
	 	US 7,043,821
	 	05/16/2006
	 
	 	 	 	 	 	 
	*LFS0208USDIV

	 	Method of
Preventing Short
Sampling of a Capillary
or Wicking Fill Device
	 	US 7,131,342
	 	11/07/2006
	 
	 	 	 	 	 	 
	*LFS0210USA

	 	Method of Filling
an Amperometric Cell
	 	US 6,592,744
	 	07/15/2003
	 
	 	 	 	 	 	 
	*LFS0210USACON

	 	Method of Filling
an Amperometric Cell
	 	US 7,041,210
	 	05/09/2006
	 
	 	 	 	 	 	 
	*LFS0211US

	 	Method and Device
for Sampling and
Analyzing Interstitial
Fluid in Whole Blood
Samples
	 	US 6,612,111
	 	09/02/2003
	 
	 	 	 	 	 	 
	LFS0211USCNT2

	 	Method and Device
for Sampling and
Analyzing Interstitial
Fluid in Whole Blood
Samples
	 	USSN 10/830,841
	 	04/22/04
	 
	 	 	 	 	 	 
	*LFS0213USA

	 	Antioxidant Sensor
	 	US 6,638,415
	 	10/28/2003
	 
	 	 	 	 	 	 
	LFS0215USA

	 	Electrochemical

Method for Measuring

Chemical Reaction Rates
	 	US 6,444,115
	 	09/03/2002
	 
	 	 	 	 	 	 
	LFS0216USA

	 	Hemoglobin Sensor
	 	US 6,632,349
	 	10/14/2003
	 
	 	 	 	 	 	 
	LFS0217USA

	 	Electrochemical Cell
	 	US 6,413,410
	 	07/02/2002
	 
	 	 	 	 	 	 
	LFS0218USA

	 	Electrochemical Cell
	 	US 6,521,110
	 	02/18/2003
	 
	 	 	 	 	 	 
	LFS0219

	 	Electrochemical Cell
	 	US 6,863,801
	 	03/08/2005
	 
	 	 	 	 	 	 
	LFS0220USAPCT

	 	Electrochemical Cell
	 	US 7,431,820
	 	10/07/2008
	 
	 	 	 	 	 	 

 

			
	*	 	Asterisk indicates cases no longer prosecuted or maintained by J&J, for which UBS declined to
assume responsibility, and that will become abandoned in due course.

A-2

 

EXHIBIT A

	 	 	 	 	 	 	 
	Current Docket

 No.	 	Title	 	Pat./Appln. No.	 	Filing/issue Date
	LFS0220USCNT1

	 	Electrochemical Cell
	 	USSN 12/196,704
	 	08/22/2008
	 
	 	 	 	 	 	 
	*LFS221USA

	 	Method and Apparatus for
Automatic Analysis
	 	US 6,852,212
	 	02/08/2005
	 
	 	 	 	 	 	 
	LFS222USCNT1

	 	Electrochemical Cell Connector
	 	US 7,846,312
	 	12/07/2010
	 
	 	 	 	 	 	 
	LFS222USNP

	 	Method of Forming an
Electrical Connection Between an
Electrochemical Cell and Meter
	 	US 6,946,067
	 	09/20/2005
	 
	 	 	 	 	 	 
	LFS223USACNT

	 	Electrochemical Cell
	 	US 6,960,289
	 	11/01/2005
	 
	 	 	 	 	 	 
	LFS223USACNT2

	 	Sensor Connector Means
	 	USSN 11/434,442
	 	05/15/2006
	 
	 	 	 	 	 	 
	LFS224USCNT

	 	Sensor Connector Means
	 	US 7,045,046
	 	05/16/2006
	 
	 	 	 	 	 	 
	*LFS228USA

	 	Heated Electrochemical Cell
	 	US 6,878,251
	 	04/12/2005
	 
	 	 	 	 	 	 
	*LFS252USACNT

	 	Method and Device for
Sampling and Analyzing
Interstitial Fluid and Whole Blood
Samples
	 	US 6,939,312
	 	09/06/2005
	 
	 	 	 	 	 	 
	LFS253USCNT

	 	Electrochemical Method for

Measuring Chemical Reaction Rates
	 	US 7,022,217
	 	04/04/20006
	 
	 	 	 	 	 	 

 

			
	*	 	Asterisk indicates cases no longer prosecuted or maintained by J&J, for which UBS declined to
assume responsibility, and that will become abandoned in due course.

A-3

 

EXHIBIT B

Patent Filing Jurisdictions

Australia

Canada

EPO:

France

Germany

Italy

Netherlands

Spain

United Kingdom

Japan

United States

 

 

EXHIBIT C

Licensed Patents

	 	 	 	 	 
	Patent Number	 	Issued Date	 	Title
	US 6,872,298

	 	March 29, 2005
	 	Determination of Sample Volume Adequacy in Biosensor Devices
	 
	 	 	 	 
	US 6,797,150

	 	September 28, 2004
	 	Determination of Sample Volume Adequacy in Biosensor Devices
	 
	 	 	 	 
	US 7,195,704

	 	March 27, 2007
	 	Determination of Sample Volume Adequacy in Biosensor Devices
	 
	 	 	 	 
	US 6,193,873

	 	February 27, 2001
	 	Sample Detection to Initiate Timing of an Electrochemical Assay
	 
	 	 	 	 
	US 6,676,995

	 	January 13, 2004
	 	Solution Striping System
	 
	 	 	 	 
	US 6,689,411

	 	February 10, 2004
	 	Solution Striping System

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]